Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: The Neuradapt study

Journal of NeuroVirology

Volumn 19, Issue 4, 2013, Pages 376-382

  Vassallo, Matteo ^a   Dunais, Brigitte ^a   Durant, Jacques ^a   Carsenti Dellamonica, Helene ^a   Harvey Langton, Alexandra ^a   Cottalorda, Jacqueline ^a   Ticchioni, Michel ^a   Laffon, Muriel ^b   Lebrun Frenay, Christine ^b   Dellamonica, Pierre ^a   Pradier, Christian ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Antiretroviral therapy; HIV associated neurocognitive disorders; Lipopolysaccharide

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; ILLICIT DRUG; LIPOPOLYSACCHARIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LABORATORY TEST; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PATIENT SELECTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84883480683     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-013-0181-y     Document Type: Article

References (24)

1. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3:e2516
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799
3. Aronow HA, Weston AJ, Pezeshki BB, Lazarus TS (2008) Effects of coinfection with HIV and hepatitis C virus on the nervous system. AIDS Read 18:43-48
4. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, Kirk GD, Mehta SH, Cox AL, Thomas DL, Ray SC (2008) Human immunodeficiency virus related microbial translocation and progression of hepatitis C. Gastroenterology 135:226-233
5. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12:1365-1371
6. Chattergoon M, Levine J, Cox A. HIV and HCV stimulate production of the inflammatory cytokine IL-18 through activation of the Nalp 3 inflammasome in monocytes. J Immunol 2012
7. Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, Moos V, Amasheh M, Loddenkemper C, Fromm M, Zeitz M, Schulzke JD (2009) Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58:220-227
8. French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN. Microbial translocation and liver disease progression in HIV/Hepatitis C co-infected women. J Infect Dis. 2013. [Epub ahead of print]
9. Goodkin K, Shapshak P et al (2009) The spectrum of Neuro-AIDS disorders: pathophysiology, diagnosis and treatment. ASM press, Washington DC
10. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) Charter group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter study. Neurology 75:2087-2096
11. Kushner LE, Wendelboe AM, Lazzeroni LC, CharY A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodnyi M. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected and HCV spontaneously cleared patients. Plos one 2012
12. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65-70
13. Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, Morgello S, Gabuzda D (2011) Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 57:371-379
14. Marchetti G (2011) ICONA foundation study group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 25:1439-1441
15. Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, Borghi F, Carosi G, Puoti M (2012) Monforte Ad. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One 7(2):e32028
16. Mc Arthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus associated neurocognitive disorders: mind the gap. Ann Neurol 67:699-714
17. Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ (2009) Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 28:369-375
18. Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L (2013) Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS One 8(2):e55776
19. Robertson KR et al (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915-1921
20. Rotman Y, Liang TJ (2009) Coinfeciton with hepatitis C and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83:7366-7374
21. Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, Aguon J, Valcour V (2005) Circulating prodigal HIV DNA and HIV-associated dementia. AIDS 19:45-52
22. Shiramizu B, Ananworanich J, Chalermchai T et al (2012) Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neurovirol 18(1):69-73
23. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM (2010) Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T cell activation following therapy. AIDS 24:1281-1290
24. Woods SP, Moore DJ, Weber E, Grant I (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19:152-168